Thomas Ciulla - 04 Jan 2023 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)

Role: Chief Medical Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: CLSD
Transactions as of: 04 Jan 2023
Net transactions value: +$11,000
Form type: 4
Filing time: 06 Jan 2023, 15:27:03 UTC
Previous filing: 28 Jan 2022
Next filing: 11 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLSD	Common Stock	Award	$6,250	+5,000	+1.7%	$1.25	302,760	30 Jun 2022	Direct	F1
transaction	CLSD	Common Stock	Award	$4,750	+5,000	+1.7%	$0.9500	307,760	31 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLSD	Employee Stock Option (right to buy)	Award	$0	+187,500		$0.000000	187,500	04 Jan 2023	Common Stock	187,500	$1.48	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2	One-fourth of the shares underlying this option vest on January 4, 2024 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.